People · Operator
Named in public records as an officer, director or promoter · active 2009–2013 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CEBIX Inc | — | Pharmaceuticals | Series B | $76.3M | $1.1B | 2009 |
| Ocera Therapeutics, Inc. | — | Pharmaceuticals | Series B | $50.0M | $952.1M | 2013 |
| ARYx Therapeutics, Inc. | — | Pharmaceuticals | Seed | $2.4M | $76.6M | 2009 |
Lars G. Ekman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lars G. Ekman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James I. Healy | 1 | 7 |
| PAUL SEKHRI | 1 | 7 |
| Michael F. Powell | 1 | 6 |
| Joel Martin | 1 | 5 |
| Eckard F. Weber | 1 | 4 |
| Paul Goddard | 1 | 4 |
| Nina S. Kjellson | 1 | 4 |
| Brenda D Gavin | 1 | 3 |
| Nick Simon | 1 | 3 |
| Keith Leonard | 1 | 3 |
| David J. Drutz | 1 | 2 |
| Jeryl L. Hilleman | 1 | 2 |
| Nina G. Kjellson | 1 | 2 |
| Linda S Grais | 1 | 2 |
| Alex D. Zisson | 1 | 2 |
| William R. Rohn | 1 | 2 |
| Paul G. Sekhri | 1 | 2 |
| Pascal Druzgala | 1 | 2 |
| Lars Ekman | 1 | 2 |
| Peter G Milner | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.